Biopharmaceutical company Xeris Biopharma Holdings Inc (Nasdaq: XERS) announced on Monday that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its subsidiary Xeris Pharmaceuticals Inc's U.S. patent application covering XP-8121. The notice confirms the application meets patentability requirements and is expected to issue as a U.S. patent, with claims specific to the XP-8121 formulation.

The company is pursuing additional US and international intellectual property protection in the levothyroxine (LT4) space.

XP-8121 is an investigational, ready-to-use liquid levothyroxine sodium formulation for once-weekly subcutaneous injection, developed using Xeris' proprietary XeriSol technology. By bypassing the gastrointestinal tract, it aims to overcome limitations of oral levothyroxine, including variable absorption, drug and food interactions, and inconsistent therapeutic effect.

Xeris markets three approved products: Recorlev for endogenous Cushing's syndrome, Gvoke for severe hypoglycemia and Keveyis for primary periodic paralysis. The company's pipeline is led by XP-8121, a Phase 3-ready therapy for hypothyroidism, alongside early-stage programs leveraging its XeriSol and XeriJect platforms. Xeris Biopharma is headquartered in Chicago, Illinois.